RxDoctor Payments Data

Bethany Fisher

Family · Atascadero, CANPI 1477743961

Payments from drug & device makers

$5,618in general payments, 2019–2025

Across 307 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • GSK$1K
  • Novo Nordisk$858
  • Lilly USA, LLC$702
  • Amgen$369
  • Pfizer$362
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$5,618100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,618 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter92$103,500
MounjaroTirzepatide79$96,224
JardianceEmpagliflozin63$80,164
OzempicSemaglutide33$49,896
Repatha SureclickEvolocumab38$41,613
XareltoRivaroxaban32$35,173
EliquisApixaban40$34,796
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog26$18,566
FarxigaDapagliflozin Propanediol11$18,389
TrulicityDulaglutide15$13,804
UbrelvyUbrogepant11$11,240
VascepaIcosapent Ethyl13$10,569
BelsomraSuvorexant11$8,740
LinzessLinaclotide11$7,577
QuviviqDaridorexant Hcl11$5,170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$702$110,02894 claims
GSKTrelegy Ellipta$1,074$103,50092 claims
Boehringer IngelheimJardiance$277$80,16463 claims
Novo NordiskOzempic$858$49,89633 claims
PfizerEliquis, Levoxyl$362$37,88595 claims
AbbVieUbrelvy, Linzess, Synthroid$1,140$21,21242 claims
MerckBelsomra$39$8,74011 claims
Idorsia Pharmaceuticals US IncQuviviq$48$5,17011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.

Other family in Atascadero

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →